KDM1A, a Potent and Selective Target, for the Treatment of DNMT3A-Deficient Non-Small Cell Lung Cancer

To investigate the role of loss-of-function mutations of DNMT3A in NSCLC, CRISPR/Cas9 was used to induce DNMT3A-inactivating mutations.